Zobrazeno 1 - 10
of 32
pro vyhledávání: '"D. S. Goodin"'
Publikováno v:
BMC Medical Genomics, Vol 14, Iss 1, Pp 1-15 (2021)
Abstract Background To study the accumulation of MS-risk resulting from different combinations of MS-associated conserved-extended-haplotypes (CEHs) of the MHC and three non-MHC “risk-haplotypes” nearby genes EOMES, ZFP36L1, and CLEC16A. Many hap
Externí odkaz:
https://doaj.org/article/d7b293af90aa4ee59890a42977371986
Autor:
D S, Goodin
Publikováno v:
Handbook of clinical neurology. 138
MS-pathogenesis involves both genetic-susceptibility and environmental determinants. Three (or more) sequential environmental-factors are implicated. The first acts near birth, the second acts during childhood/adolescence, and the third acts subseque
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f4b4a633e3181fe8eaf5adde289784b1
https://pubmed.ncbi.nlm.nih.gov/27637959
https://pubmed.ncbi.nlm.nih.gov/27637959
Publikováno v:
Neurology. 69:1553-1555
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44bc72a744849ed2696185dc26c133eb
https://doi.org/10.1212/01.wnl.0000295671.79239.f1
https://doi.org/10.1212/01.wnl.0000295671.79239.f1
Publikováno v:
Neurology. 59:471-473
To the Editor: In their evaluation of disease modifying therapies in MS, Goodin et al.1 question the validity of observations that brain atrophy is delayed in the second year of treatment with weekly intramuscular interferon β-1a (Avonex).2 They sta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5463ba94cc0c79cdc5ff4fb052651246
https://doi.org/10.1212/wnl.59.3.471
https://doi.org/10.1212/wnl.59.3.471
Autor:
G C, Ebers, A, Traboulsee, D, Li, D, Langdon, A T, Reder, D S, Goodin, T, Bogumil, K, Beckmann, C, Wolf, A, Konieczny, A, Riddlebough
Publikováno v:
Journal of Neurology, Neurosurgery and Psychiatry
Journal of Neurology, Neurosurgery and Psychiatry, BMJ Publishing Group, 2010, 81 (8), pp.907. ⟨10.1136/jnnp.2009.204123⟩
Journal of Neurology, Neurosurgery and Psychiatry, BMJ Publishing Group, 2010, 81 (8), pp.907. ⟨10.1136/jnnp.2009.204123⟩
International audience; Background: Evidence for efficacy of disease-modifying drugs in multiple sclerosis (MS) comes from trials of short duration. We report results from a 16-year, retrospective follow-up of the pivotal interferon beta-1b (IFNB-1b)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::378309df38db0fdf0728e3c77fa4d9f7
http://ora.ox.ac.uk/objects/uuid:ee58537a-0581-4114-8830-fdaf8d065335
http://ora.ox.ac.uk/objects/uuid:ee58537a-0581-4114-8830-fdaf8d065335
Autor:
A T, Reder, G C, Ebers, A, Traboulsee, D, Li, D, Langdon, D S, Goodin, T, Bogumil, K, Beckmann, A, Konieczny, A, Riddlebough
Publikováno v:
Neurology. 74(23)
OBJECTIVE: The 16-Year Long-Term Follow-Up (LTF) to the pivotal interferon-beta-1b (IFNbeta-1b) trial explored clinical, MRI, cognitive, and patient-reported outcomes. Here, we report the safety assessments. METHODS: In the pivotal study, 372 patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::480153e704cdf6d9e375ac4f6fd95a05
http://ora.ox.ac.uk/objects/uuid:936bc4d2-a199-426a-a7d8-373332af2ef1
http://ora.ox.ac.uk/objects/uuid:936bc4d2-a199-426a-a7d8-373332af2ef1
Publikováno v:
Neurology. 54:1393-1395
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86152f4c73ddea76d6e9835f730aa455
https://doi.org/10.1212/wnl.54.6.1393
https://doi.org/10.1212/wnl.54.6.1393
Autor:
D S, Goodin
Publikováno v:
International MS journal. 12(3)
Evidence-based medicine (EBM) describes a structured (non-consensus-based) process, in which medical literature is assessed critically to define the value of different therapeutic interventions. Ultimately, the goal is to improve both physician decis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::01428fffbec509f449419d0b149f8f22
https://pubmed.ncbi.nlm.nih.gov/16422017
https://pubmed.ncbi.nlm.nih.gov/16422017
Autor:
D S, Goodin
Publikováno v:
International MS journal. 12(3)
The present manuscript uses an evidence-based approach to review and analyse evidence for the use of human beta interferon in the treatment of MS. Human beta interferon modulates many of the biological processes believed to be involved in MS developm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d5b7768b3a3712b72fd1c84d6706d5b2
https://pubmed.ncbi.nlm.nih.gov/16417818
https://pubmed.ncbi.nlm.nih.gov/16417818
Autor:
D S, Goodin, E M, Frohman, G P, Garmany, J, Halper, W H, Likosky, F D, Lublin, D H, Silberberg, W H, Stuart, S, van den Noort
Publikováno v:
Neurology. 58(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::30831d672791e8d23f125bb804746c6f
https://pubmed.ncbi.nlm.nih.gov/12184316
https://pubmed.ncbi.nlm.nih.gov/12184316